US ENT Partners is leading the way in expanding access to advanced biologic therapies through its strategic partnership with Amgen, bringing TEZSPIRE® (tezepelumab-ekko) to ENT and allergy practices nationwide.
As nasal polyposis and chronic inflammatory airway conditions continue to impact patient outcomes, US ENT Partners is focused on helping practices adopt innovative treatments like TEZSPIRE® while simplifying the operational challenges that come with them.
This partnership reflects a clear mission: empowering ENT practices with the access, infrastructure, and support needed to deliver better patient outcomes.
Transforming Nasal Polyp Treatment Through Biologics
TEZSPIRE® represents a major advancement in the treatment of severe asthma and related inflammatory conditions, including nasal polyps. For ENT specialists, this opens new opportunities to treat patients who previously had limited options.
US ENT Partners plays a central role in making this possible by:
- Connecting practices directly with leading pharmaceutical partners like Amgen
- Streamlining access to biologic therapies such as TEZSPIRE®
- Supporting reimbursement and payer navigation
- Reducing operational barriers to adoption
By bridging the gap between innovation and execution, US ENT Partners ensures practices can focus on patient care rather than administrative complexity.
Simplifying Biologics Access for ENT Practices
One of the biggest challenges in adopting biologics is not clinical, it is operational.
US ENT Partners helps practices overcome this by:
- Improving access pathways for TEZSPIRE®
- Simplifying prior authorizations and reimbursement workflows
- Reducing administrative burden across teams
- Creating more efficient, scalable processes for biologics management
This enables ENT and allergy practices to confidently integrate biologics into their treatment strategies.
Industry Recognition: ASCENT Highlights US ENT Partners
The impact of this partnership is gaining recognition across the ENT community.
The ASCENT | Administrator Support Community for ENT, a highly influential organization in otolaryngology practice management, has highlighted US ENT Partners’ collaboration with Amgen and the role of TEZSPIRE® in treating nasal polyps.
You can view ASCENT’s spotlight here:
https://www.linkedin.com/posts/ask-ascent_ent-practicemanagement-biologics-activity-7439687053585534977-Tesp
ASCENT’s recognition reinforces the importance of strong operational partnerships in enabling practices to successfully adopt biologics. It also highlights US ENT Partners as a key player supporting ENT practices in this evolving treatment landscape.
Strengthening ENT Practices Through Strategic Partnerships
US ENT Partners is not just enabling access to therapies. It is building a stronger foundation for ENT practices.
Through partnerships like the one with Amgen, US ENT Partners helps practices:
- Adopt innovative treatments like TEZSPIRE®
- Improve outcomes for patients with nasal polyps and severe asthma
- Optimize operations and reduce inefficiencies
- Stay competitive in a rapidly evolving healthcare environment
Leading the Future of ENT Biologics
As biologics continue to reshape ENT and allergy care, US ENT Partners remains at the forefront.
By combining strategic partnerships, operational support, and a deep understanding of ENT practice needs, US ENT Partners is helping define how modern practices deliver advanced, patient-centered care.
With Amgen and TEZSPIRE®, and with recognition from organizations like ASCENT, US ENT Partners continues to lead the way in supporting ENT practices nationwide.